Cargando…

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001

As an exceedingly recalcitrant and highly aggressive tumor type without Food and Drug Administration-approved treatment or a known cure, the prognosis of recurrent extensive stage platinum-resistant/refractory small cell lung cancer (SCLC) is worse than other types of lung cancer, and many other tum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oronsky, Bryan, Caroen, Scott, Zeman, Karen, Quinn, Mary, Brzezniak, Christina, Scicinski, Jan, Cabrales, Pedro, Reid, Tony R., Trepel, Jane B., Abrouk, Nacer D., Larson, Christopher, Oronsky, Arnold, Lybeck, Harry E., Day, Regina M., Carter, Corey A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5098407/ https://www.ncbi.nlm.nih.gov/pubmed/27840583 http://dx.doi.org/10.4137/CMO.S40429

Ejemplares similares

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor
por: Brzezniak, Christina, et al.
Publicado: (2017)

Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME)
por: Reid, Tony, et al.
Publicado: (2023)

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
por: Carter, Corey A., et al.
Publicado: (2016)

RRx-001 in Refractory Small-Cell Lung Carcinoma: A Case Report of a Partial Response after a Third Reintroduction of Platinum Doublets
por: Carter, Corey A., et al.
Publicado: (2016)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
por: Fine, Howard, et al.
Publicado: (2023)

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells
por: Oronsky, Bryan, et al.
Publicado: (2018)

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization
por: Carter, Corey A., et al.
Publicado: (2016)

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001
por: Carter, Corey A., et al.
Publicado: (2016)

Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor
por: Carter, Corey A., et al.
Publicado: (2015)

RRx-001, A novel dinitroazetidine radiosensitizer
por: Oronsky, Bryan, et al.
Publicado: (2016)

Complete metabolic response of metastatic castration‐resistant neuroendocrine carcinoma of the prostate after treatment with RRx‐001 and reintroduced platinum doublets
por: Ojemuyiwa, Michelle, et al.
Publicado: (2018)

RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic"
por: Oronsky, Bryan, et al.
Publicado: (2020)

Desperate Times, Desperate Measures: The Case for RRx-001 in the Treatment of COVID-19
por: Oronsky, Bryan., et al.
Publicado: (2020)

RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist
por: Oronsky, Bryan, et al.
Publicado: (2023)

RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report
por: Brzezniak, Christina, et al.
Publicado: (2016)

RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors
por: Oronsky, Bryan, et al.
Publicado: (2016)

Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats
por: Caroen, Scott, et al.
Publicado: (2022)

In small cell lung cancer patients treated with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells significantly correlates with clinical benefit
por: Tomita, Yusuke, et al.
Publicado: (2021)

Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx‐001
por: Oronsky, Bryan, et al.
Publicado: (2018)

RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature
por: Jani, Vinay P., et al.
Publicado: (2021)

From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria
por: Yalcin, Ozlem, et al.
Publicado: (2015)

A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation
por: Jayabalan, Nanthini, et al.
Publicado: (2023)

No patient left behind: The promise of immune priming with epigenetic agents
por: Carter, Corey A., et al.
Publicado: (2017)

RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice
por: Jurgensen, Kimberly J., et al.
Publicado: (2021)

Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity
por: Zhao, Hongjuan, et al.
Publicado: (2015)

Two Case Reports of Resensitization to Previous Chemotherapy with the Novel Hypoxia-Activated Hypomethylating Anticancer Agent RRx-001 in Metastatic Colorectal Cancer Patients
por: Reid, T., et al.
Publicado: (2014)

Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors
por: Raghunand, Natarajan, et al.
Publicado: (2017)

The War on Cancer: A Military Perspective
por: Oronsky, Bryan, et al.
Publicado: (2015)

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man—PFS2: A Measure of Therapeutic Action-At-A-Distance
por: Oronsky, Bryan, et al.
Publicado: (2015)

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents
por: Oronsky, Bryan, et al.
Publicado: (2016)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
por: Cottrill, Hope, et al.
Publicado: (2018)

A 2022 Update on Extensive Stage Small-Cell Lung Cancer (SCLC)
por: Oronsky, Bryan, et al.
Publicado: (2022)

NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001()
por: Scicinski, Jan, et al.
Publicado: (2015)

Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
por: Ning, Shoucheng, et al.
Publicado: (2015)

The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry
por: Zhao, Hongjuan, et al.
Publicado: (2017)

Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001
por: Hammond, Terese Catherine, et al.
Publicado: (2022)

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies
por: Carter, Corey A., et al.
Publicado: (2016)

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management
por: Oronsky, Bryan, et al.
Publicado: (2017)

Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial()(): A TITE-CRM Phase I/II Clinical Trial
por: Kim, Michelle M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1q2oce1g8h767rr61v505829rc